Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 21

1.

Towards improved solubility of poorly water-soluble drugs: cryogenic co-grinding of piroxicam with carrier polymers.

Penkina A, Semjonov K, Hakola M, Vuorinen S, Repo T, Yliruusi J, Aruväli J, Kogermann K, Veski P, Heinämäki J.

Drug Dev Ind Pharm. 2016;42(3):378-88. doi: 10.3109/03639045.2015.1054400. Epub 2015 Jun 11.

PMID:
26065533
2.

Targeted treatment with a combination of traditional DMARDs produces excellent clinical and radiographic long-term outcomes in early rheumatoid arthritis regardless of initial infliximab. The 5-year follow-up results of a randomised clinical trial, the NEO-RACo trial.

Rantalaiho V, Kautiainen H, Korpela M, Hannonen P, Kaipiainen-Seppänen O, Möttönen T, Kauppi M, Karjalainen A, Laiho K, Laasonen L, Hakola M, Peltomaa R, Leirisalo-Repo M; NEO-RACo Study Group.

Ann Rheum Dis. 2014 Nov;73(11):1954-61. doi: 10.1136/annrheumdis-2013-203497. Epub 2013 Aug 1.

PMID:
23908187
3.

Direct compression of cellulose and lignin isolated by a new catalytic treatment.

Penkina A, Antikainen O, Hakola M, Vuorinen S, Repo T, Yliruusi J, Veski P, Kogermann K, Heinämäki J.

AAPS PharmSciTech. 2013 Sep;14(3):1129-36. doi: 10.1208/s12249-013-0002-x. Epub 2013 Jul 19.

4.

A novel alkaline oxidation pretreatment for spruce, birch and sugar cane bagasse.

Kallioinen A, Hakola M, Riekkola T, Repo T, Leskelä M, von Weymarn N, Siika-aho M.

Bioresour Technol. 2013 Jul;140:414-20. doi: 10.1016/j.biortech.2013.04.098. Epub 2013 May 6.

PMID:
23711947
5.

From hazardous waste to valuable raw material: hydrolysis of CCA-treated wood for the production of chemicals.

Hakola M, Kallioinen A, Leskelä M, Repo T.

ChemSusChem. 2013 May;6(5):813-5. doi: 10.1002/cssc.201200754. Epub 2013 Apr 3.

PMID:
23554264
6.

Solid-state properties of softwood lignin and cellulose isolated by a new acid precipitation method.

Penkina A, Hakola M, Paaver U, Vuorinen S, Kirsimäe K, Kogermann K, Veski P, Yliruusi J, Repo T, Heinämäki J.

Int J Biol Macromol. 2012 Dec;51(5):939-45. doi: 10.1016/j.ijbiomac.2012.07.024. Epub 2012 Jul 27.

PMID:
22846687
7.

Liberation of cellulose from the lignin cage: A catalytic pretreatment method for the production of cellulosic ethanol.

Hakola M, Kallioinen A, Kemell M, Lahtinen P, Lankinen E, Leskelä M, Repo T, Riekkola T, Siika-aho M, Uusitalo J, Vuorela S, von Weymarn N.

ChemSusChem. 2010 Oct 25;3(10):1142-5. doi: 10.1002/cssc.201000217. No abstract available.

PMID:
20853392
8.

Sustained remission and reduced radiographic progression with combination disease modifying antirheumatic drugs in early rheumatoid arthritis.

Mäkinen H, Kautiainen H, Hannonen P, Möttönen T, Leirisalo-Repo M, Laasonen L, Korpela M, Blåfield H, Hakola M, Sokka T.

J Rheumatol. 2007 Feb;34(2):316-21. Epub 2006 Dec 15.

PMID:
17183623
9.

Serum soluble interleukin-2 receptor predicts early remission in patients with recent-onset rheumatoid arthritis treated with a single disease-modifying antirheumatic drug.

Kuuliala A, Leirisalo-Repo M, Möttönen T, Hannonen P, Nissilä M, Kautiainen H, Korpela M, Julkunen H, Hakola M, Repo H; FIN-RACo Trial Group.

Clin Exp Rheumatol. 2005 Mar-Apr;23(2):243-6.

PMID:
15895898
10.

Effect of a three month course of ciprofloxacin on the late prognosis of reactive arthritis.

Yli-Kerttula T, Luukkainen R, Yli-Kerttula U, Möttönen T, Hakola M, Korpela M, Sanila M, Uksila J, Toivanen A.

Ann Rheum Dis. 2003 Sep;62(9):880-4.

11.

Effect of a three month course of ciprofloxacin on the outcome of reactive arthritis.

Yli-Kerttula T, Luukkainen R, Yli-Kerttula U, Möttönen T, Hakola M, Korpela M, Sanila M, Parviainen J, Uksila J, Vainionpää R, Toivanen A.

Ann Rheum Dis. 2000 Jul;59(7):565-70.

12.

Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. FIN-RACo trial group.

Möttönen T, Hannonen P, Leirisalo-Repo M, Nissilä M, Kautiainen H, Korpela M, Laasonen L, Julkunen H, Luukkainen R, Vuori K, Paimela L, Blåfield H, Hakala M, Ilva K, Yli-Kerttula U, Puolakka K, Järvinen P, Hakola M, Piirainen H, Ahonen J, Pälvimäki I, Forsberg S, Koota K, Friman C.

Lancet. 1999 May 8;353(9164):1568-73.

PMID:
10334255
13.

Sulfasalazine in early rheumatoid arthritis. A 48-week double-blind, prospective, placebo-controlled study.

Hannonen P, Möttönen T, Hakola M, Oka M.

Arthritis Rheum. 1993 Nov;36(11):1501-9.

PMID:
7902092
14.

Cervical spine rotation and lateral flexion combined motion in the examination of the thoracic outlet.

Lindgren KA, Leino E, Hakola M, Hamberg J.

Arch Phys Med Rehabil. 1990 Apr;71(5):343-4. Erratum in: Arch Phys Med Rehabil 1990 Jul;71(8):582.

PMID:
2327890
15.

Reactive oligoarthritis associated with Clostridium difficile colitis.

Hannonen P, Hakola M, Möttönen T, Oka M.

Scand J Rheumatol. 1989;18(1):57-60. No abstract available.

PMID:
2784867
16.

Urinary neopterin index as a measure of rheumatoid activity.

Hannonen P, Tikanoja S, Hakola M, Möttönen T, Viinikka L, Oka M.

Scand J Rheumatol. 1986;15(2):148-52.

PMID:
3749827
17.

Palindromic rheumatism in two non-identical brothers with identical HLA including DR4.

Hannonen P, Hakola M, Oka M.

Ann Rheum Dis. 1985 Mar;44(3):202-4.

18.

A clinical study of the anxiolytic effect of dixyrazine (Esucos).

Hakola ML, Hakola P.

Int J Neuropsychiatry. 1967 Jun;3(3):219-25. No abstract available.

PMID:
5340606
19.

A clinical study of the anxiolytic effect of dixyrazine (Esucos).

Hakola ML, Hakola P.

Acta Neurol Psychiatr Belg. 1967;67:Suppl:37-47. No abstract available.

PMID:
4964201
20.

[Dixyrazine (Esucos) in the treatment of anxiety neuroses].

Hakola ML, Hakola P.

Duodecim. 1966;82(18):885-91. Finnish. No abstract available.

PMID:
5924983
21.

[Clinical studies of the anxiety relieving effect of dixyrazine].

Hakola ML, Hakola P.

Nord Psykiatr Tidsskr. 1966;20(4):325-33. Swedish. No abstract available.

PMID:
5341430

Supplemental Content

Loading ...
Support Center